GlassScriptPhysician profile
Syed H Jafri
NPI 1770785982
$975.59
in general payments reported to CMS, 2019-2025
16 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.32 · 2021: $379 · 2022: $109 · 2023: $28.05 · 2024: $207 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $230.15 | 2024-2025 | |
| Seagen INC. | $181.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.23 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $140.81 | 2021-2025 | Opdivo |
| Tempus Ai, INC | $51.84 | 2025 | Xt Cdx |
| Tactile Systems Technology INC | $41.36 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.32 | 2019 | |
| Immunocore Limited | $28.05 | 2023 | Kimmtrak |
| Ipsen Biopharmaceuticals, INC | $26.73 | 2024 | Iqirvo |
| Celgene Corporation | $24.91 | 2025 | Opdivo |
| Gilead Sciences, INC. | $21.17 | 2024 | |
| Genmab U.S., INC. | $18.01 | 2025 | Epkinly |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.21 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.82 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Jafri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.